SkinHealth Systems Inc. (NASDAQ: SKIN), the parent company of Hydrafacial, saw its stock fall 3.4% to $0.643 on June 3, 2026, remaining below the $1 minimum bid price required for continued Nasdaq listing. The company has until November 4, 2026, to regain compliance. Despite the launch of a new scalp treatment, HydraScalp with Keravive, the stock decline reflects broader market weakness and investor concerns about declining sales and device demand.
Stock and Listing Status
SkinHealth Systems shares traded at $0.6425 in late-morning action on June 3, with volume of approximately 336,000 shares and a market capitalization near $84.5 million. The company received a Nasdaq deficiency notice in May after its stock traded below $1 for 30 consecutive business days from March 26 to May 7. To regain compliance, the closing bid price must remain at or above $1 for at least 10 consecutive business days. If it fails, SkinHealth may consider a reverse stock split, which would raise the share price but does not address underlying demand, margins, or cash flow.
HydraScalp Launch and Market Positioning
On June 2, SkinHealth announced the launch of HydraScalp with Keravive, a non-invasive in-office scalp treatment that uses Hydrafacial's Vortex-Fusion technology and biomimetic peptides. The treatment is now available at select Hydrafacial providers across the United States. Whitney Cypes, chief brand and clinical innovation officer, cited a "surge in demand for scalp health," while dermatologist Corey Hartman noted that "the scalp is an extension of your skin." The company aims to expand Hydrafacial's application beyond facial treatments, but it remains unclear whether this will translate into steady clinic bookings and device sales.
Financial Performance and Outlook
SkinHealth reported first-quarter 2026 net sales of $64.9 million, down from $69.6 million a year earlier. Delivery systems sold fell to 746 from 862, and consumables sales also declined. CEO Pedro Malha described the market as "challenging" but said "the fundamentals are intact." The company projects full-year 2026 net sales of $280 million to $295 million, with adjusted EBITDA between $35 million and $45 million. Adjusted EBITDA excludes interest, taxes, depreciation, amortization, and certain other items.
What Buyers Should Watch
For overseas distributors and clinic buyers, the key signal is whether HydraScalp drives incremental demand for Hydrafacial systems and consumables. If the treatment gains traction among providers, it could stabilize device sales and consumables revenue. However, the broader weakness in elective aesthetics—reflected in InMode's stock decline as well—suggests that clinic capital expenditure may remain cautious. Buyers should monitor SkinHealth's next quarterly results for evidence of HydraScalp adoption and its impact on device and consumables orders.
Regulatory and Channel Signals
Nasdaq's delisting risk adds pressure on SkinHealth to demonstrate operational improvement. A reverse stock split, if pursued, would not change the company's fundamentals. The consensus Wall Street rating remains Hold, with Roth Capital maintaining a $2.00 price target. Competitive pressure appears limited, as the stock weakness aligns with a softer tape for elective-aesthetics suppliers rather than a direct reaction to the HydraScalp launch. Broader U.S. market declines, driven by geopolitical risk, higher oil prices, and labor-market data, have further weighed on small-cap healthcare and consumer-device stocks.
Source: Read the original report | Published: June 03, 2026